Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Traneurocin - NeuroActiva

Next Previous
Drug Profile

Traneurocin - NeuroActiva

Alternative Names: BIOCOVAX; BIOMEDIVIR; DEXANEUROSONE; NA 831; NA-81; NANOMEDIVIR; NEUROSIVIR; TRANEUROCINE

Latest Information Update: 25 Sep 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NeuroActiva
  • Developer Biomed Industries; Florey Institute of Neuroscience and Mental Health; NeuroActiva
  • Class Antidementias; Antivirals; Neuroprotectants; Nootropics; Peptides; Small molecules
  • Mechanism of Action AMPA receptor agonists; Neurogenesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III COVID 2019 infections
  • Phase II Alzheimer's disease; Fragile X syndrome; Rett syndrome
  • Phase I Major depressive disorder
  • No development reported Neurological disorders

Most Recent Events

  • 25 Sep 2024 Chemical structure information added.
  • 28 Jul 2024 Efficacy and adverse event data from phase II trial in Alzheimer’s Disease and Major Depressive Disorder presented at the Alzheimer's Association International Conference 2024 (AAIC-2024)
  • 06 Oct 2023 Phase-II clinical trials in Fragile X syndrome (unspecified route) (Biomed Industries pipeline, October 2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top